Financial reports
10-Q
2024 Q3
Quarterly report
12 Nov 24
10-Q
2024 Q2
Quarterly report
13 Aug 24
10-Q
2024 Q1
Quarterly report
10 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
30 Mar 23
Current reports
8-K
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
12 Nov 24
8-K
Ocuphire Pharma Announces Acquisition of Opus Genetics
22 Oct 24
8-K
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
13 Aug 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Jun 24
8-K
Regulation FD Disclosure
10 May 24
8-K
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10 May 24
8-K
Departure of Directors or Certain Officers
17 Apr 24
8-K
Regulation FD Disclosure
27 Mar 24
8-K
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8 Mar 24
8-K
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
16 Feb 24
Registration and prospectus
D
$25.78 mm in equity, sold $25.78 mm, 11 investors
7 Nov 24
S-8
Registration of securities for employees
4 Nov 24
424B3
Prospectus supplement
16 Feb 24
S-8
Registration of securities for employees
11 Jan 24
S-3
Shelf registration
10 Jan 24
S-8
Registration of securities for employees
20 Nov 23
424B5
Prospectus supplement for primary offering
14 Aug 23
S-8
Registration of securities for employees
5 Apr 23
S-8
Registration of securities for employees
5 Apr 22
424B5
Prospectus supplement for primary offering
7 Jun 21
Proxies
DEFR14A
Revised proxy
30 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
10 Jun 22
DEFA14A
Additional proxy soliciting materials
2 Jun 22
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
26 Apr 21
Other
EFFECT
Notice of effectiveness
24 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
19 Jan 24
UPLOAD
Letter from SEC
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
28 Jun 23
EFFECT
Notice of effectiveness
16 Feb 21
CORRESP
Correspondence with SEC
11 Feb 21
UPLOAD
Letter from SEC
10 Feb 21
EFFECT
Notice of effectiveness
5 Oct 20
Ownership
4
George Magrath
5 Nov 24
SC 13D
Foundation Fighting Blindness Retinal Degeneration Fund
29 Oct 24
3
Initial statement of insider ownership
29 Oct 24
4
Adrienne L Graves
24 Oct 24
4
Jean Bennett
24 Oct 24
3
BENJAMIN R YERXA
24 Oct 24
3
Adrienne L Graves
24 Oct 24
3
Jean Bennett
24 Oct 24
4
Richard J Rodgers
13 Jun 24
4
Jay Pepose
13 Jun 24